Advancing community stakeholder engagement in biomedical HIV prevention trials: Principles, practices and evidence

Expert Review of Vaccines

Volumn 13, Issue 12, 2014, Pages 1553-1562

  Newman, Peter A ^a   Rubincam, Clara ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Clinical trials; Community engagement; Community participation; Ethics; Hiv prevention; Hiv vaccines; Low income countries; Mistrust; Social sciences; Stakeholder engagement

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

BEHAVIORAL SCIENCE; CLINICAL TRIAL (TOPIC); COMMUNITY; COMMUNITY STAKEHOLDER ENGAGEMENT; GOOD CLINICAL PRACTICE; GOOD PARTICIPATORY PRACTICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTEGRATION; LOWEST INCOME GROUP; PRACTICE GUIDELINE; PREVENTION STUDY; REVIEW; SOCIOLOGY; CONSUMER; HIV INFECTIONS; IMMUNOLOGY;

AIDS VACCINES; CLINICAL TRIALS AS TOPIC; CONSUMER PARTICIPATION; HIV INFECTIONS; HUMANS;

EID: 84909581907     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.953484     Document Type: Review

References (57)

1. UNAIDS-AVAC. Good participatory practice: guidelines for biomedical HIV prevention trials 2007. Joint United Nations Programme on HIV/AIDS (UNAIDS); Geneva: 2007
2. UNAIDS-AVAC. Good participatory practice: guidelines for biomedical HIV prevention trials 2011. Joint United Nations Programme on HIV/AIDS (UNAIDS); Geneva: 2011
3. Flicker S, Savan B, McGrath M, et al. If you could change one thing: what community-based researchers wish they could have done differently. Community Dev J 2008;43(2):239-53
4. Marsh V, Kamuya D, Rowa Y, et al. Beginning community engagement at a busy biomedical research programme: experiences from the KEMRI CGMRC-Wellcome Trust Research Programme, Kilifi, Kenya. Soc Sci Med 2008;67(5):721-33
5. Morin SF, Maiorana A, Koester KA, et al. Community consultation in HIV prevention research: a study of community advisory boards at 6 research sites. J Acquir Immune Defic Syndr 2003;33(4):513-20
6. Tindana PO, Singh JA, Tracy CS, et al. Grand challenges in global health: community engagement in research in developing countries. PLoS Med 2007;4(9):e273
7. McGrory E, Irvin A, Heise L. Research Rashomon, lessons from the Cameroon pre-exposure prophylaxis trial site, 2009. Available from: www.global-campaign.org/clientfiles/Cameroon.pdf [Last accessed 29 July 2014]
8. Newman PA. Towards a science of community engagement. Lancet 2006;367(9507):302
9. Ragin DF, Ricci E, Rhodes R, et al. Defining the 'community' in community consultation for emergency research: findings from the community VOICES study. Soc Sci Med 2008;66(6):1379-92
10. Jewkes R, Murcott A. Meanings of community. Soc Sci Med 1996;43(4):555-63
11. Participants in the community engagement and consent workshop, Kilifi, Kenya, March 2011. Consent and community engagement in diverse research contexts. J Empir Res Hum Res Ethics 2013;8(4):1-18
12. Sharp RR, Foster MW. Involving study populations in the review of genetic research. J Law Med Ethics 2010;28(1):41-51
13. Bandewar SV, Kimani J, Lavery JV. The origins of a research community in the Majengo Observational Cohort Study, Nairobi, Kenya. BMC Public Health 2010;10(1):630
14. Gikonyo C, Bejon P, Marsh V, Molyneux S. Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan Coast. Soc Sci Med 2008;67(5):708-20
15. Bardhan P, Ray I. The contested commons: conversations between economists and anthropologists. Blackwell Publishing; Oxford: 2008
16. Cashman SB, Adeky S, Allen AJ, et al. The power and the promise: working with communities to analyze data, interpret findings, and get to outcomes. Am J Public Health 2008;98(8):1407-17
17. Nind M. Participatory data analysis: a step too far? Qual Res 2011;11(4):349-63
18. Flicker S, Nixon SA. The DEPICT model for participatory qualitative health promotion research analysis piloted in Canada, Zambia and South Africa. Health Promot Int 2014. [Epub ahead of print]
19. Koen J, Essack Z, Slack C, et al. It looks like you just want them when things get rough: civil society perspectives on negative trial results and stakeholder engagement in HIV prevention trials. Dev World Bioeth 2013;13(3):138-48
20. Flory J, Emanuel E. Interventions to improve research participants' understanding in informed consent for research: a systematic review. JAMA 2004;292(13):1593-601
21. Lindegger G, Milford C, Slack C, et al. Beyond the checklist: assessing understanding for HIV vaccine trial participation in South Africa. J Acquir Immune Defic Syndr 2006;43(5):560-6
22. Chakrapani V, Newman PA, Singhal N, et al. If it's not working, why would they be testing it? : mental models of HIV vaccine trials and preventive misconception among men who have sex with men in India. BMC Public Health 2013;13(1):731
23. Delany-Moretlwe S, Stadler J, Mayaud P, Rees H. Investing in the future: lessons learnt from communicating the results of HSV/HIV intervention trials in South Africa. Health Res Policy Syst 2011;9(s8):1-9
24. Mack N, Robinson ET, MacQueen KM, et al. The exploitation of "Exploitation" in the tenofovir prep trial in Cameroon: lessons learned from media coverage of an HIV prevention trial. J Empir Res Hum Res Ethics 2010;5(2):3-19
25. Newman PA, Logie C, James L, et al. Speaking the dialect: understanding public discourse in the aftermath of an HIV vaccine trial shutdown. Am J Public Health 2011;101(9):1749-58
26. Essack Z, Koen J, Slack C, et al. Civil society perspectives on negative biomedical HIV prevention trial results and implications for future trials. AIDS Care 2012;24(10):1249-54
27. Streefland P, Chowdhury AM, Ramos-Jimenez P. Patterns of vaccination acceptance. Soc Sci Med 1999;49(12):1705-16
28. Leach M, Fairhead J. Vaccine anxieties: global science, child health and society. Earthscan; London: 2007
29. Leach M, Fairhead J. Understandings of immunization: some West African perspectives. Bull World Health Organ 2008;86(6):418
30. Newman PA. Integrating social and biomedical science in HIV vaccine research: obstacles, opportunities and ways forward. Expert Rev Vaccines 2012;11(1):1-3
31. Lindegger G, Quayle M, Ndlovu M. Local knowledge and experiences of vaccination: implications for HIV-preventive vaccine trials in South Africa. Health Educ Behav 2007;34(1):108-23
32. Krieger JL, Parrott RL, Nussbaum JF. Metaphor use and health literacy: a pilot study of strategies to explain randomization in cancer clinical trials. J Health Commun 2011;16(6):3-6
33. Lally M, Goldsworthy R, Sarr M, et al. Evaluation of an intervention among adolescents to reduce preventive misconception in HIV vaccine clinical trials. J Adolesc Health 2014;55(2):254-9
34. Belsky L, Richardson HS. Medical researchers' ancillary clinical care responsibilities. BMJ 2004;328(7454):1494-6
35. Hyder AA, Merritt MW. Ancillary care for public health research in developing countries. JAMA 2009;302(4):429-31
36. Participants in the 2006 Georgetown University workshop on the ancillary-care obligations of medical professionals working in developing countries. The ancillary-care obligations of medical researchers working in developing countries. PLoS Med 2008;5(5):e90
37. Richardson HS, Belsky L. The ancillary-care responsibilities of medical researchers: an ethical framework for thinking about the clinical care that researchers owe their subjects. Hastings Cent Rep 2004;34(1):25-33
38. Shapiro K, Benatar S. HIV prevention research and global inequity: steps towards improved standards of care. J Med Ethics 2005;31(1):39-47
39. Pace C, Grady C, Wendler D, et al. Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses 2006;22(9):837-41
40. Slack CM. Ancillary care in South African HIV vaccine trials: addressing needs, drafting protocols, and engaging community. J Empir Res Hum Res Ethics 2014;9(1):83-95
41. MacQueen KM, McLoughlin K, Alleman P, et al. Partnering for care in HIV prevention trials. J Empir Res Hum Res Ethics 2008;3(4):5-18
42. Newman PA, Lee SJ, Roungprakhon S, Tepjan S. Demographic and behavioral correlates of HIV risk among men and transgender women recruited from gay entertainment venues and community-based organizations in Thailand: implications for HIV prevention. Prev Sci 2012;13(5):483-92
43. Chakrapani V, Newman PA, Shunmugam M, Dubrow R. Barriers to free antiretroviral treatment access among kothi-identified men who have sex with men and aravanis (transgender women) in Chennai, India. AIDS Care 2011;23(12):1687-94
44. Newman PA, Chakrapani V, Weaver J, et al. Willingness to participate in HIV vaccine trials among diverse men who have sex with men in Chennai and Mumbai, India. Vaccine; 2014, in press
45. Ciaranello AL, Walensky RP, Sax PE, et al. Access to medications and medical care after participation in HIV clinical trials: a systematic review of trial protocols and informed consent documents. HIV Clin Trials 2009;10(1):13-24
46. Emanuel EJ; Participants in the 2001 Conference on Ethical Aspects of Research in Developing Countries. Moral standards for research in developing countries from 'reasonable availability' to 'fair benefits'. Hastings Cent Rep 2004;34(3):17-27
47. Benatar SR, Singer PA. Responsibilities in international research: a new look revisited. J Med Ethics 2010;36(4):194-7
48. International AIDS Vaccine Initiative (IAVI). Training manual: guidance tool for community advisory boards. IAVI; New York: 2012
49. Rigon A. Building local governance: participation and elite capture in slum-upgrading in Kenya. Dev Change 2014;45(2):257-83
50. Jewkes R, Murcott A. Community representatives: representing the 'community'? Soc Sci Med 1998;46(7):843-58
51. Nichter M. Project community diagnosis: participatory research as a first step toward community involvement in primary health care. Soc Sci Med 1984;19(3):237-52
52. Ellen JM, Wallace M, Sawe FK, Fisher K. Community engagement and investment in biomedical HIV prevention research for youth: rationale, challenges, and approaches. J Acquir Immune Defic Syndr 2010;54(Suppl 1):S7-11
53. Epstein S. Impure science: AIDS, activism, and the politics of knowledge. Reprint eds University of California Press; Berkeley: 1998
54. Geffen N. Debunking delusions: the inside story of the treatment action campaign. Jacana Media; Cape Town: 2010
55. Haire B, Folayan MO, Hankins C, et al. Ethical considerations in determining standard of prevention packages for HIV prevention trials: examining PrEP. Dev World Bioeth 2013;13(2):87-94
56. Economist. Pharmed out: why the row over giant drug company takeovers misses the point. The Economist, 2014. Available from: www.economist.com/node/21602689/print [Last accessed 29 July 2014]
57. Fee E, Parry M. Jonathan Mann, HIV/AIDS, and human rights. J Public Health Policy 2008;29(1):54-71